Cipla News

Cipla has reported negative weekly returns on its share price.

Cipla's US unit has partnered with China's Qilu Pharmaceutical to license QL2107, a biosimilar of Merck's cancer drug Keytruda, for commercialization in the US,

Cipla has announced a partnership with China's Qilu Pharma to develop and commercialize a cancer biosimilar, reinforcing Cipla's focus on its oncology portfolio

Aurobindo Pharma, through its Lannett Company, has launched a generic version of Advair Diskus in the US for asthma and COPD, marking its first complex inhalati

Several major stocks, including HDFC Bank, Reliance, Augmont, M&M, and Ola Electric, are expected to be in focus on Monday, August 31st.

The Bombay High Court has criticized the Maharashtra FDA's enforcement actions against various businesses, including Cipla, questioning due process and proporti

The Bombay High Court criticized the Maharashtra FDA for its high-handed actions and restored Cipla Pharma's drug sale license, which had been cancelled without

The Bombay High Court rebuked the Maharashtra FDA for its handling of Cipla and five eateries, leading the FDA to withdraw its orders against them. The court em

The Maharashtra FDA has withdrawn its order to cancel Cipla Pharma's drug sale license after the Bombay High Court criticized its actions. The FDA will now issu

The Maharashtra FDA has cancelled Cipla's drug sale licences for its Pune facility due to violations found during an investigation, including mislabelling of pr

AIMIM ने तेलंगाना MLC मिर्जा रहमत बेग को पार्टी से निष्कासित कर दिया है। त्रिपुरा के पश्चिमी जिले में 5 सितंबर से मतदाता सूची का विशेष गहन पुनरीक्षण शुरू होगा।

The Maharashtra FDA, led by Tukaram Mundhe, canceled a Cipla unit's drug license for Reactin Plus due to irregularities found during a June inspection, specific

सिप्ला की पुणे यूनिट का ड्रग लाइसेंस रद्द कर दिया गया है। तुकाराम मुंढे ने सख्त कार्रवाई की बात कही और गड़बड़ियों का खुलासा किया।

The Maharashtra FDA has cancelled the licence of Cipla's Pune unit.

The Maharashtra FDA has canceled Cipla's Pune unit drug sale license due to irregularities related to Reactin Plus, leading to the seizure of drug stock worth R

The Maharashtra Food and Drug Administration has revoked Cipla's drug license for its Pune unit due to violations in packaging and storage practices, specifical

Indian markets closed flat amidst mixed signals, with PB Fintech reporting increased profits, ONGC preparing deals with Venezuela, and Ola Electric and Cipla in

Cipla and Rocket India announced a ₹300 crore investment for manufacturing facilities in Karnataka, while Blackstone is exploring data center and renewable ener

Cipla has received U.S. FDA approval for a generic version of an asthma and COPD drug, marking its first dry powder inhaler approval from its U.S.-based manufac

Markets extended their losing streak for a fourth consecutive session, with Infosys reporting a 12% year-on-year profit growth in Q1, while Cipla's net profit f

Cipla anticipates a ramp-up in US sales by FY27 and maintains its full-year Ebitda margin guidance of 18.5-20%, with plans to launch key new products.

Cipla is prioritizing its tirzepatide brand Yurpeak in the Indian obesity market, which has become the second-largest GLP-1 product since its launch. The compan

Cipla reported a 39% drop in net profit for the June quarter, primarily due to weakness in its North America business and margin compression, despite record rev

Cipla's Q1 FY27 profit decreased by 39% year-over-year to ₹789 crore, despite a 3.50% increase in revenue from product sales.